Brucellosis presenting as myelofibrosis: First case report  by Bakri, Faris G. et al.
CASE REPORT
Brucellosis presenting as myelofibrosis:
First case report
Faris G. Bakri a,*, Nazzal M. Al-Bsoul b, Ahmad Y. Magableh b,
Asem Shehabi c, Musleh Tarawneh d, Azmy M. Al-Hadidy e,
Mohammed A. Abu-Fara a, Abdallah S. Awidi b
aDepartment of Medicine, Division of Infectious Diseases, Jordan University Hospital, PO Box 13046, Amman 11942, Jordan
bDepartment of Medicine, Division of Hematology and Oncology, Jordan University Hospital, Amman, Jordan
cDepartment of Pathology—Microbiology, Jordan University Hospital, Amman, Jordan
dDepartment of Pathology, Jordan University Hospital, Amman, Jordan
eDepartment of Radiology, Jordan University Hospital, Amman, Jordan
Received 8 January 2009; received in revised form 8 March 2009; accepted 15 March 2009
Corresponding Editor: Ziad Memish, Riyadh, Saudi Arabia
International Journal of Infectious Diseases (2010) 14, e158—e160
http://intl.elsevierhealth.com/journals/ijid
KEYWORDS
Brucella;
Pancytopenia;
Myelofibrosis;
Bone marrow
Summary We describe the case of a 29-year-old woman who presented with pancytopenia and
myelofibrosis. Brucella melitensis was identified in her blood. The patient recovered completely
with doxycycline and rifampin. A repeat bone marrow biopsy showed hypercellularity without
myelofibrosis. Bone marrow findings in cases of pancytopenia due to brucellosis reveal normo-
cellularity, hypercellularity, hemophagocytosis, or granuloma. To our knowledge this is the first
report of brucellosis causing myelofibrosis. Brucellosis should be considered as a possible cause of
myelofibrosis in endemic areas.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Brucellosis is a major zoonotic disease in several parts of the
world including the Mediterranean region; it can affect any
organ and can have various presentations.1,2 Pancytopenia is
a known complication of brucellosis.2,3 Causes of pancyto-
penia in brucellosis include hypersplenism and/or bone mar-
row involvement with granuloma, hemophagocytosis, and
rarely bone marrow hypoplasia.4,5* Corresponding author. Tel.: +962 6 5353666x2474;
fax: +962 6 5353388.
E-mail address: fbakri@yahoo.com (F.G. Bakri).
1201-9712/$36.00 # 2009 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2009.03.018Here, we describe a case of brucellosis presenting with
pancytopenia secondary to myelofibrosis. To our knowledge
this is the first report of such a complication resulting from
brucellosis.
Case report
A 29-year-old woman, who used to drink raw milk, was
healthy until July 2007 when she started to complain of
fever, dry cough, arthralgia, loss of appetite, and generalized
weakness. She presented to our hospital one month after the
onset of her symptoms.Published by Elsevier Ltd. All rights reserved.
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blood pressure of 125/80 mmHg, temperature 38.5 8C, hepa-
tosplenomegaly, purpuric rash on the lower extremities, and
a tender and swollen left knee. Laboratory examination
showed hemoglobin 7.5 g/dl, white blood cell count
1.3  109/l (neutrophils 37%, lymphocytes 55%), and plate-
lets 20.8  109/l. A blood film showed dimorphic red blood
cells and no blast cells. Lactate dehydrogenase was 1479 U/l
(normal range 240—480 U/l). Both the prothrombin and par-
tial thromboplastin times were normal. Coombs’ test was
positive. Tests for hepatitis viruses B and C and HIV were all
negative.
A bone marrow biopsy (Figure 1) revealed myelofibrosis
with proliferative phase. Initially, the patient received imi-
penem and fluconazole (days 1—2), which was then switched
to ceftazidime and caspofungin (days 3—9). However, the
patient remained febrile. Eight days after admission, a blood
culture (BACTEC 9240) taken on the day of admission grew
Brucella melitensis identified by culture, Gram staining,
biochemical, and serotyping methods. Therefore, doxycy-
cline 100 mg twice daily and rifampin 600 mg once daily were
started, and her fever abated after 2 days. The serum
agglutination titer for Brucella was 320. A transthoracicFigure 2 Bone marrow biopsy after treatment showing (A)
marked hypercellularity (H&E 20); (B) reticulin not increased
in the marrow (reticulin, 20).
Figure 1 Bone marrow biopsy before treatment showing (A)
fibrosis and hypocellular elements (H&E 20); (B) marked fibro-
sis (reticulin, 20).echocardiogram did not show any vegetation. Abdominal
computed tomography (CT) showed hepatosplenomegaly
with a liver size of 19 cm and spleen size of 22 cm. A chest
CT showed right hilar lymphadenopathy.
The patient finished 3 months of doxycycline and rifam-
pin. Her hemoglobin rose to 13 g/l, white blood cell count to
5.8  109/l, and platelets to 101  109/l. A repeat bone
marrow biopsy (Figure 2) in November 2007 showed hyper-
cellular marrow with no evidence of fibrosis, malignancy, or
granulomatous process. A repeat CT of the abdomen in May
2008 showed spleen and liver sizes of 16 cm. The patient
continued to do well one year following her initial presenta-
tion. Her spleen became non-palpable and her repeat Bru-
cella titer was 40.
Discussion
Infection with Brucella is known to cause anemia, leukope-
nia, and to a lesser extent thrombocytopenia and pancyto-
penia. The frequency of pancytopenia ranges from 3% to
21%.6 Bone marrow findings in cases complicated by pancy-
topenia include normocellular or hypercellular marrow, gran-
uloma, hemophagocytosis, and rarely hypoplasia.3—11 In
e160 F.G. Bakri et al.these situations, neutropenia resolves following treatment of
the infection. The cause of pancytopenia is poorly under-
stood. However, due to the tendency to marrow hyperplasia,
and splenomegaly and absence of hemolysis, hypersplenism
was implicated as the cause of pancytopenia; it is also
possible that Brucella organisms exert a direct inhibitory
effect on marrow cells or they induce lymphocytes to release
mediators that inhibit hematopoeisis.5,9
Considering that brucellosis can occur with leukemia,
febrile neutropenia, and solid tumors,4,12,13 we could not
determine initially whether the patient had myelofibrosis
secondary to brucellosis, or the brucellosis occurred in a
preexisting myelofibrosis. However, the remarkable clinical
and bone marrow response after the treatment of the infec-
tion support the hypothesis that Brucella was the cause of the
myelofibrosis.
To our knowledge, this is the first report of myelofibrosis
due to brucellosis. Myelofibrosis can be seen in a variety of
conditions, including chronic granulocytic leukemia, acute
myeloid leukemia, multiple myeloma, and chronic lympho-
cytic leukemia. Infectious causes include kala-azar,14 disse-
minated tuberculosis, histoplasmosis,15 and Epstein—Barr
virus.16 Myelofibrosis can occur in cases of tuberculosis either
due to hemophagocytosis,8 or through the effect of trans-
forming growth factor (TGF)-b which is produced from the
tuberculosis granuloma and promotes fibrosis in the bone
marrow.17
The mechanism of development of myelofibrosis here is
not completely understood. We did not find any evidence of
hemophagocytosis in the bone marrow; therefore the devel-
opment of myelofibrosis could be due to overproduction of
cytokines such as TGF-b. In this regard Rafiei et al.18 reported
that patients with brucellosis have an increased frequency of
TGF-b1 high producer genotype, but on the other hand
Akbulut et al.19 did not find significant differences in TGF-
b levels between controls and patients with brucellosis.
Alternatively, myelofibrosis could occur secondary to an anti-
body-mediated autoimmune mechanism.20 In support of this
possibility is the positive Coombs’ test, and the fact that
brucellosis has been described with several autoimmune
conditions such as glomerulonephritis,21 Henoch—Schonlein
purpura,22 and thrombocytopenia.23
In conclusion, this is the first report describing brucellosis
complicated by myelofibrosis. Physicians in endemic areas
should be aware of this possible association and test for
Brucella in cases of myelofibrosis.
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